Henri Merdjan

Executive Director, Integrated Drug Development


Paris, France

About Henri Merdjan

Dr. Merdjan joined Certara in 2010 after 25 years of new drug development in the industry, working successively for Sandoz, Servier France, and Servier UK, where he served as the General Manager of the DMPK Center and as the Acting Head of the Modeling & Simulation (M&S) Department. Merdjan was Vice President of DMPK at Novexel, a successful biotech company. He has experience in various therapeutic areas including infectious disease, cardiovascular, central nervous system, oncology, and metabolic and musculoskeletal diseases. His experience covers the whole spectrum of drug development phases from discovery to post-launch and includes some exposure to regulatory authorities, mainly with the E.M.A. and the F.D.A.. Prior to joining the industry, Merdjan spent over five years in hospital residency, where he practiced therapeutic drug monitoring and clinical pharmacokinetics (PK). Over the years, Dr. Merdjan has been an invited lecturer in PK and pharmacokinetics/pharmacodynamics (PK/PD) at the School of Pharmacy in Paris, the School of Medicine in Basle, and at the Cefira, a private training institute. He earned his Pharm.D. from the University of Paris and holds a certificate in Clinical Pharmacology and methodology of clinical trials. To date, Merdjan has co-authored over 80 publications, book chapters and communications in the field of bioanalysis, drug metabolism, PK, PK/PD and M&S.